A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 27 Sep 2013
At a glance
- Drugs Pazopanib (Primary)
- Indications CNS cancer; Ewing's sarcoma; Gastric cancer; Head and neck cancer; Pelvic cancer; Soft tissue sarcoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 27 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 May 2012 Planned end date changed from 1 Dec 2010 to 1 May 2013 as reported by ClinicalTrials.gov.
- 23 May 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.